Drug Profile
PWT 33597
Alternative Names: PWT-33597; PWT33597 mesylateLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pathway Therapeutics
- Class Antineoplastics
- Mechanism of Action MTOR protein inhibitors; Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (PO)
- 14 Nov 2011 Pharmacodynamics data from a preclinical trial in Cancer presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC)
- 01 Jun 2011 Phase-I clinical trials in Solid tumours in USA (PO)